Health Care

Insider sale of 75 Becton Dickinson shares by Chief Revenue Officer Michael Feld shows a routine, small‑scale trade—no red flag yet for BDX investors.

Insider buying at Thermo Fisher Scientific signals confidence in its mid‑growth outlook, boosting investor sentiment.

Thermo Fisher CFO’s 1,534‑share buy signals management’s confidence and a potential short‑term upside amid dividend hikes and positive market sentiment.

Farley Brian’s recent insider sale at Acadia Healthcare shows routine small‑scale divestment, not a red flag, and offers investors insight into executive liquidity needs and confidence amid steady earnings and moderate profitability.

Insider sale of IDEXX shares by EVP Hunt Nimrata shows routine rebalancing, not a confidence shift – a stable sign for investors in veterinary diagnostics.

Prime Medicine insider buys signal CEO confidence in a big biotech win – 1.3 M stock options, rising share price, and growing market sentiment show a promising next phase.

CEO insider sell‑off sparks debate on UniQure’s gene‑therapy outlook, raising questions about management confidence amid strong market gains.

Inovio insider moves reveal a liquidity‑focused strategy: chief scientific officer Humeau Laurent buys and sells RSUs, hinting at short‑term cash needs while still backing the company’s vaccine pipeline.

Insider buying surge at Myriad signals confidence amid volatility: 104,000+ shares purchased, potential upside, and strategic pipeline insights.

UroGen insider buying signals optimism amid strong clinical data: insider purchases, positive sentiment, and upcoming conference highlight potential upside, but investors should watch regulatory risks.